Faster ulcer healing indicated in results of amniotic membrane allograft study
A study by Skye® Biologics El Segundo, CA, USA) has indicated a 98% complete wound healing rate in ulcer patients within 12 weeks of using WoundEx® FastActing Membrane, a dehydrated human amniotic membrane allograft aimed at treating chronic diabetic foot and venous leg ulcers.
A pilot study investigating the use of Skye® Biologics’ (El Segundo, CA, USA) proprietary dehydrated human amniotic membrane tissue allograft for the treatment of lower extremity wounds has indicated that the WoundEx® FastActing Membrane™ results in accelerated healing in diabetic foot and venous leg ulcers. The company has announced that the study has shown a 98% complete wound heal rate within 12 weeks.
The US healthcare system reports that refractory nonhealing wounds are a significant burden. Diabetic foot ulcers are the main cause of nontraumatic lower extremity amputation and in 2012 cost the USA US$245 billion. Venous leg ulcers are even more common and affect over 2 million individuals each year. Standard treatments for these wound types include debridement, collagens and pressure relief, to name a few.
The study, led by Dr Eric Lullove of the West Boca Center for Wound Healing (FL, USA), included 20 male and female patients with chronic nonhealing wounds that had a larger than average wound size. They were treated using conventional methods initially to clear the wound of bioburden, with WoundEx application at weeks 1, 3 and 5, if needed. Reduction in wound size with WoundEx treatment was seen in 46% of patients at 4 weeks, with 98% wound closure recorded at 12 weeks.
The FastActing WoundEx Amniotic Membrane is described as a skin substitute formulated using next-generation scientific methods to support tissue reformulation while keeping pain and inflammation in check and reducing scarring. Lullove elaborates: “it performs remarkably well to advance and progress these wounds to healing. I have used various types of tissue biologics in my practice, and this is now my go-to tissue for advanced wound healing.”
It is hoped that technologies such as this will enable patients with chronic diabetic and venous ulcers to have a better chance at more efficient wound healing in conjunction with traditional techniques.
Note, at the time of writing, the results of the study, indicated as a peer-reviewed pilot study, were on file.
– Written By Zara Parker
Source: Skye® Biologics Announces WoundEx® Membrane Recent Study Reveals Accelerated Wound Closure Rates: http://www.prweb.com/releases/2016/11/prweb13840082.htm